Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Home Depot Inc (HD) vs Mesoblast Limited (MESO) Price & Performance

Home Depot IncTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

Home Depot Inc vs Mesoblast Limited — how do they compare? Home Depot Inc trades at $291.6 (market cap $294.79B), while Mesoblast Limited trades at $14.32 (market cap $1.75B). The key difference: Home Depot Inc is far larger — about 168.5× Mesoblast Limited's market cap, and Home Depot Inc pays a 3.15% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Home Depot Inc for 139 Days and Mesoblast Limited for 14 Days on average.

HDMESO
Market Cap
$294.79B$1.75B
Volume
8,693,917239,027
Sector
Consumer CyclicalHealth
52-Week High
$391.90$20.96
52-Week Low
$281.15$13.19
Typical Hold Time
139 Days14 Days
Enterprise Value
$355.27B$1.83B
Dividend Yield
3.15%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Home Depot Inc

Home Depot (HD) trades at $291.17, up 1.89% today, with a bullish technical signal but mixed moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $4.92 exceeding expectations. Revenue for 2025 reached $159.51 billion, though net income margin has trended down to 8.41%. Analyst consensus is bullish with a $379.93 price target, but rising mortgage rates and weak big-ticket demand pose headwinds.

The outlook remains cautiously optimistic given HD's robust profitability and Pro business growth, but margin pressure and housing market sensitivity are key risks. Institutional activity shows mixed positioning, with some firms increasing stakes while others trim holdings. The stock's valuation at a P/E of 20.68 appears reasonable if earnings momentum continues.

Mesoblast Limited

MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.

While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HD
100% Buy0% Sell
Avg holding period · 139 Days
MESO

No sentiment data available yet.

Top news

Latest headlines on both assets

About Home Depot Inc

Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.

Read more on HD →

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO →